PE20120781A1 - Formulacion de omeprazol farmaceutica estable para administracion oral - Google Patents

Formulacion de omeprazol farmaceutica estable para administracion oral

Info

Publication number
PE20120781A1
PE20120781A1 PE2012000062A PE2012000062A PE20120781A1 PE 20120781 A1 PE20120781 A1 PE 20120781A1 PE 2012000062 A PE2012000062 A PE 2012000062A PE 2012000062 A PE2012000062 A PE 2012000062A PE 20120781 A1 PE20120781 A1 PE 20120781A1
Authority
PE
Peru
Prior art keywords
agent
oral administration
stable pharmaceutical
omeprazole
omeprazole formulation
Prior art date
Application number
PE2012000062A
Other languages
English (en)
Inventor
Erik Juvonen
Louis Massimo Micolucci
Original Assignee
Vetegen Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43465734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120781(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vetegen Llc filed Critical Vetegen Llc
Publication of PE20120781A1 publication Critical patent/PE20120781A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA DE JARABE PARA ADMINISTRACION ORAL QUE COMPRENDE: A) OMEPRAZOL; B) UN AGENTE SOLUBILIZANTE TAL COMO POLIETILENGLICOL 200, GLICEROL, SORBITOL, ENTRE OTROS; C) UN AGENTE BASIFICANTE TAL COMO MONOETANOLAMINA, DIETANOLAMINA, ENTRE OTROS; D) UN AGENTE EDULCORANTE TAL COMO SUCRALOSA, SACARINA, ENTRE OTROS; E) UN AGENTE AROMATIZANTE; F) UN ANTIOXIDANTE TAL COMO GALATO DE PROPILO; G) UN AGENTE ANTIMICROBIANO TAL COMO ACIDO BENZOICO Y BENZOATO DE SODIO; H) UN POTENCIADOR DE LA SOLUBILIDAD TAL COMO CICLODEXTRINA, POLISORBATO 80, ENTRE OTROS; E I) UN MODIFICADOR DE LA VISCOSIDAD TAL COMO HIDROXIPROPILMETILCELULOSA, GOMA XANTANA, ENTRE OTROS
PE2012000062A 2009-07-20 2010-07-20 Formulacion de omeprazol farmaceutica estable para administracion oral PE20120781A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22689009P 2009-07-20 2009-07-20

Publications (1)

Publication Number Publication Date
PE20120781A1 true PE20120781A1 (es) 2012-06-27

Family

ID=43465734

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000062A PE20120781A1 (es) 2009-07-20 2010-07-20 Formulacion de omeprazol farmaceutica estable para administracion oral

Country Status (11)

Country Link
US (1) US8530500B2 (es)
EP (1) EP2456439A4 (es)
JP (1) JP2012533633A (es)
AU (1) AU2010276404A1 (es)
CA (1) CA2768024A1 (es)
CL (1) CL2012000169A1 (es)
CO (1) CO6491061A2 (es)
EC (1) ECSP12011618A (es)
IN (1) IN2012DN00359A (es)
PE (1) PE20120781A1 (es)
WO (1) WO2011011351A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201402796SA (en) * 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
GB201306720D0 (en) 2013-04-12 2013-05-29 Special Products Ltd Formulation
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
GB2561355A (en) * 2017-04-10 2018-10-17 Eaststone Ltd Pharmaceutical composition and a method for manufacturing the same
CN107397719A (zh) * 2017-08-16 2017-11-28 洛阳市兽药厂 一种畜禽用奥美拉唑可溶性粉剂及其制备工艺
GB2585628A (en) * 2019-05-08 2021-01-20 Alkaloid Ad Pharmaceutical formulation
GB2616663A (en) * 2022-03-18 2023-09-20 Alkaloid Ad Skopje Pharmaceutical formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
DE60009675T2 (de) * 1999-02-23 2005-03-24 Merck & Co., Inc. Protonenpumpinhibitoren enthaltende zusammensetzung
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR045068A1 (es) 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
CA2561700A1 (en) 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8865692B2 (en) * 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation

Also Published As

Publication number Publication date
WO2011011351A3 (en) 2011-05-19
EP2456439A4 (en) 2012-12-26
US8530500B2 (en) 2013-09-10
CO6491061A2 (es) 2012-07-31
CL2012000169A1 (es) 2012-08-31
US20110015233A1 (en) 2011-01-20
IN2012DN00359A (es) 2015-05-22
EP2456439A2 (en) 2012-05-30
ECSP12011618A (es) 2012-04-30
CA2768024A1 (en) 2011-01-27
WO2011011351A2 (en) 2011-01-27
JP2012533633A (ja) 2012-12-27
AU2010276404A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
PE20120781A1 (es) Formulacion de omeprazol farmaceutica estable para administracion oral
PE20100254A1 (es) Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona
PE20110010A1 (es) Formulaciones liquidas de fenilefrina
NZ596657A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
CR20110617A (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
ECSP11011555A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
TW200738277A (en) Liquid formulations
MX369121B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
CL2011001225A1 (es) Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros.
AR074391A1 (es) Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral
AR025434A1 (es) Formulacion farmaceutica con contenido de derivados de benzamida, con solubilidad y absorcion oral mejoradas
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
CO6630134A2 (es) Formulación orales y sales lipofílicas de metilnaltrexona
PE20130245A1 (es) Composicion de hidrogel de dexibuprofeno transdermico
WO2011110939A3 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
RS54659B1 (en) PHARMACEUTICAL DOSAGE FORM CONTAINING 6-FLUORO- (N-METHYL-OR N, N-DIMETHYL) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PIRANO [ 3,4, B] INDOL] -4-AMIN
MX354647B (es) Composicion farmaceutica anticonvulsiva transnasal que comprende un anticonvulsivante escasamente soluble.
PE20200698A1 (es) Gel que comprende clorhexidina
ECSP10010167A (es) Composiciones oftálmicas novedosas
RU2015115127A (ru) Жидкие лекарственные композиции апиксабана
CO6321158A2 (es) Formulacion oral
CR20140314A (es) Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metalsunfonil- etil]-4-acetil aminoisoindolin-1,3-diona
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
AR066905A1 (es) Administracion intranasal de asenapina y composiciones farmaceuticas correspondientes
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato

Legal Events

Date Code Title Description
FC Refusal